Conferences
Advertisement
Dr. Loibl discusses the importance of involving nurses in breast cancer treatment to mitigate medication side effects.
Chronic GVHD can increase the risk of infections, graft failure, and multi-organ dysfunction in patients.
The open-label phase 2 clinical trial enrolled 33 patients with resectable, high-risk ccRCC.
Optimal management of non-clear cell renal cell carcinoma remains an unmet need.
While RCC is the leading cause of cancer-related mortality, early detection can greatly improve disease outcomes.
Amanda Brink, DNP, APRN, FNP-BC, AOCNP, unpacks a key question: why do liver metastases influence immunotherapy response?
Dr. Darabos highlighted that a lack of social support in patients with cancer is associated with adverse health outcomes.
Researchers investigated if a frailty index could assess for associations between toxicity, clinical outcomes, and frailty.
Research is currently limited on how GLP-1 receptor agonists affect ICI efficacy in patients with cancer.
The phase 3 study is the longest follow-up—9 years—of a first-line checkpoint inhibitor combination in advanced RCC.
Palliative care researchers discuss breast cancer palliative care disparities among Hispanic subgroups.
Researchers predicted that sMAdCAM-1 could be used as a prognostic biomarker in ICI-based therapy for patients with mRCC.
Patients with ccRCC were randomly selected to receive pembrolizumab or placebo and categorized by risk for metastasis.
Oncology social workers performed resource-intensive screening to assess distress in patients with gynecologic cancers.
Demographics, regional trends, and disparities in endometrial cancer-related mortality for women in the US were investigated.
The study evaluated whether geographic barriers to care or psychological distress may contribute to delayed diagnosis.
The study evaluated the effect of pretreatment emotional distress on OS among more than 3,000 patients with solid tumors.
After the NuGenA program was implemented, the team of researchers extended their outreach to South Asia and South Africa.
APP-First was created to assist in testing completion and referrals before a new patient meets with a surgical oncologist.
Because it is used to detect kidney injuries, researchers evaluated KIM-1 as a liquid-based biomarker in patients with RCC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.